LAS VEGAS, May 6, 2011 /PRNewswire/ -- Cord Blood America, Inc. (OTC BB: CBAI, CBAID) announced today that the effective date for the reverse split, approved by 80 percent of its shareholders voting in a recent proxy vote, is the opening of the market on Monday, May 9, 2011.
The one for one hundred reverse split reduces the number of shares outstanding from 6,907,863, 254 shares to 69,078,710 shares.
A "D" will be placed on the ticker symbol for 20 business days, after which the symbol will revert back to the original symbol.
The transfer agent, Interwest Transfer, is available at 801.272.9294 to answer questions about individual accounts and to issue new stock certificates.
Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT: Paul KnopickE & E [email protected]949.707.5365
SOURCE Cord Blood America, Inc.
Advertisement
The one for one hundred reverse split reduces the number of shares outstanding from 6,907,863, 254 shares to 69,078,710 shares.
A "D" will be placed on the ticker symbol for 20 business days, after which the symbol will revert back to the original symbol.
Advertisement
The transfer agent, Interwest Transfer, is available at 801.272.9294 to answer questions about individual accounts and to issue new stock certificates.
Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT: Paul KnopickE & E [email protected]949.707.5365
SOURCE Cord Blood America, Inc.
